Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 4Thoracic 2Other solid neoplasm 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Lung Neoplasms 2Pleural Effusion, Malignant 1Ovarian Neoplasms 1Mesothelioma 1Breast Neoplasms 1

Interventions

pembrolizumab 156Carboplatin 146Cisplatin 129Pemetrexed 103Paclitaxel 89Nivolumab 71Radiotherapy 68Docetaxel 61Erlotinib Hydrochloride 58Gemcitabine 57Etoposide 44osimertinib 43Bevacizumab 43Cyclophosphamide 42durvalumab 41atezolizumab 35Cetuximab 33130-nm albumin-bound paclitaxel 26Radiosurgery 25fludarabine 23Ipilimumab 23Irinotecan 21Taxes 20Radiation 20Oxaliplatin 20Magnetic Resonance Spectroscopy 20Fluorouracil 20Gefitinib 19Everolimus 19Topotecan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Valacyclovir × Thoracic × Clear all
NCT03131037 2025-07-11

Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer

Candel Therapeutics, Inc.

Phase 1 Completed
12 enrolled
Thoracic

Lung Neoplasms

NCT01997190 2023-08-25

MpeTK01

Candel Therapeutics, Inc.

Phase 1 Completed
19 enrolled
BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Lung Neoplasms, Mesothelioma, Ovarian Neoplasms, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡